Health Technology Assessment/Health Benefit Package Survey 2020

Dear Respondent,

In response to the World Health Assembly Resolution 67.23, a baseline Global Survey was completed in 2015 which enabled the WHO Secretariat to assess the status of Health Technology Assessment (HTA) in Member States. The results of the 2015 Global Survey can be accessed in the Global Report (https://www.who.int/health-technology-assessment/MD_HTA_oct2015_final_web2.pdf?ua=1). WHO is now seeking to update the results of this survey, by collecting current information about the status of HTA and health benefits package (HBP) selection processes in Member States. Additionally, we are collecting information on the contents of Health Benefit Packages. For background information about the WHA resolution and the framework underlying this survey, please review this presentation - [Introduction - CLICK HERE (https://www.slideshare.net/secret/L6IUSguXHrpY9T)].

Filling out this survey is estimated to take approximately 60-90 minutes of your valuable time. This survey has a total of 8 content sections asking about: health financing and health benefit package arrangements, HTA processes and barriers, and information on the contents of the HBP. At the very end we also ask for your authorization to use the information you have provided.

The questions can all be answered by the same person or answered in a group. We recommend that you utilize multiple people for these responses if you don't feel like you can address a section accurately. You can stop the survey at any time and save your answers at which time you'll be asked to create a log-in. If needed, you may forward the link and log-in information to other respondents who might be better suited to respond to a section. For instance, you may need to do this to answer the "Contents of Health Benefit Package" section relating to a specific health financing scheme. Please note that once the survey has been submitted it is no longer possible to modify the answers unless you contact us directly. A more detailed presentation on completing this survey is available here [How to Answer - CLICK HERE (https://www.slideshare.net/secret/HOkV42IG9W0osj)].

Your effort is very important to guide the WHO Secretariat and other partners regarding future planning and development of HTA/HBP guidelines and benchmarks, as well as to ensure that current information is available in your country's profile (https://www.who.int/health-technology-assessment/country-profile/en/). A synthesis of the responses to this survey will also be made available in the survey report.

If you need assistance or have any concerns, you can contact <a href="https://

| • | _ | - | | • | |
|----------------------|---|---|--|---|--|
| | | | | | |
| | | | | | |
| Thank you very much! | | | | | |
| Thank you very much: | | | | | |
| | | | | | |

[1] NOTE: For the purpose of this survey medical devices include: in-vitro diagnostics and laboratory equipment, imaging equipment, single use devices, and assistive devices.

There are 184 questions in this survey.

Respondent Information

| 1 Please provide the following information - | * | First Name - Last Name - Country - |
|--|---|--|
|--|---|--|

| 2 w | Vhat is your primary professional background? | |
|------|---|--|
| Plea | ase choose all that apply: | |
| | Economist | |
| | Statistician | |
| | Public Health Specialist | |
| | Medical Degree | |
| | Other clinical qualification | |
| | Epidemiologist | |
| | Administration/Planning | |
| | Other: | |
| You | may select a maximum of 2 options. | |

| } Vhat is you | r primary organization or affiliation? |
|------------------|--|
| Please cho | pose all that apply and provide a comment: |
| Govern | ment - Ministry of Health |
| | |
| Other G | Government Ministry/Agency |
| | |
| Interna | tional not-for-profit organization (iNGO) |
| | |
| Nationa | al or Sub-national not-for-profit organization (NGO) |
| | |
| Internat | tional Organization (incl. United Nations) |
| | |
| Consul | tancy firm/consultant |
| | |
| Acaden | nic Institution |
| | |
| Other | |
| | |
| ou MUST s | specify/give full name of your organisation. |

| method of contact? | tact you after the | survey nas | s been com | pleted, wha | at is your p | oreferred |
|--|---------------------|-------------------|------------|-----------------------|--------------|--------------------|
| Please choose all that | apply and provid | le a comm | ent: | | | |
| E-mail | | | | | | |
| | | | | | | |
| Phone | | | | | | |
| | | | | | | |
| Skype | | | | | | |
| | | | | | | |
| Place provide a roomen | so in the how see | omnanvina | the ention | solostod | | |
| Please provide a respon | se in the box acco | ompanying | tne option | seiectea | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| 5 | | | 41. | | 4 1 1 41- | 4 4 |
| 5 If you have collaborated information and affiliatio | | | = | /, please lis | st below th | e contact |
| If you have collaborated | | | = | <i>y</i> , please lis | t below th | e contact |
| If you have collaborated | n of all individual | s who con Last | tributed. | | | Survey Sections |
| If you have collaborated information and affiliatio | n of all individual | s who con | tributed. | y, please lis | | Survey |
| If you have collaborated | n of all individual | s who con Last | tributed. | | | Survey Sections |
| If you have collaborated information and affiliatio | n of all individual | s who con Last | tributed. | | | Survey Sections |
| If you have collaborated information and affiliatio | n of all individual | s who con Last | tributed. | | | Survey Sections |
| If you have collaborated information and affiliatio | n of all individual | s who con Last | tributed. | | | Survey Sections |
| If you have collaborated information and affiliation Contributor 1 Contributor 2 Contributor 3 | n of all individual | s who con Last | tributed. | | | Survey Sections |
| If you have collaborated information and affiliation Contributor 1 | n of all individual | s who con Last | tributed. | | | Survey Sections |
| If you have collaborated information and affiliation Contributor 1 Contributor 2 Contributor 3 | n of all individual | s who con Last | tributed. | | | Survey Sections |

HTA Institutions and Governance

The space available is limited but please feel free to write outside the boxes and utilise any empty space.

| | 6 Does your country have a systematic formal process by which information is gathered to support healthcare decision-making? * |
|---|--|
| | Please choose all that apply: |
| | Yes, at the national level |
| | Yes, at the subnational level |
| | None |
| • | NOTE: The process can be within a committee, unit, department or an established HTA organization at a national or subnational level. |
| • | Decision-making here refers to a process for inclusion in Health benefit packages for provision or for reimbursement of health services |
| • | Please answer the remainder of the survey for the national level process. If you do not have a national level process, only then answer for the subnational level process. If you selected None, please proceed to the next question. |
| • | Subnational Scheme refers to a regional or state level scheme. |
| | 7 Since you answered 'No' to having a systematic formal process |
| | 7 Since you answered 'No' to having a systematic formal process for information gathering to support healthcare decision-making, we will now ask a few questions about any processes that you do have in place (please note, that you only need to answer to the best degree possible. If there are no processes in place at all, please say so). Only answer this question if the following conditions are met: Answer was 'None' at question '6 [HTAIG1]' (Does your country have a systematic formal process by which information is gathered to support healthcare decision-making?) |
| | for information gathering to support healthcare decision-making, we will now ask a few questions about any processes that you do have in place (please note, that you only need to answer to the best degree possible. If there are no processes in place at all, please say so). Only answer this question if the following conditions are met: Answer was 'None' at question '6 [HTAIG1]' (Does your country have a systematic formal |

| 9 Can you indicate whether there are plans for implementing a systematic formal process and if so, what that time-frame is? |
|---|
| Only answer this question if the following conditions are met: Answer was 'None' at question '6 [HTAIG1]' (Does your country have a systematic formal process by which information is gathered to support healthcare decision-making?) |
| Please choose only one of the following: |
| There is no plan to implement such a process |
| There will be a process in place in less than 1 year |
| There will be a process in place in 1-2 years |
| There will be a process in place in 3-5 years |
| There will be a process in place in more than 5 years. |
| |
| |

10

What entities(e.g. organizations/individuals/officials) are involved in any decisions regarding inclusion or exclusion of health technologies and interventions? For each, please state what functions they perform? Functions could include: identifying interventions, assessing evidence, appraising evidence, and making recommendations.

Only answer this question if the following conditions are met:

Answer was 'None' at question '6 [HTAIG1]' (Does your country have a systematic formal process by which information is gathered to support healthcare decision-making?)

| | Title of Entity | Functions Performed |
|----------|-----------------|---------------------|
| Entity1 | | |
| Entity 2 | | |
| Entity 3 | | |
| Entity 4 | | |
| Entity 5 | | |

The space available is limited but please feel free to write outside the boxes and utilise any empty space.

| Are any prioritization criteria used to determine which health technologies and interventions are considered in government health schemes in the country? If yes, please describe them in the box. |
|---|
| Only answer this question if the following conditions are met: Answer was 'None' at question '6 [HTAIG1]' (Does your country have a systematic formal process by which information is gathered to support healthcare decision-making?) |
| Please choose only one of the following: |
| Yes |
| ○ No |
| Make a comment on your choice here: |
| |
| |
| |
| |
| |
| |
| |
| |

| 12 Is evidence collected for making decisions about the inclusion or exclusion of health technologies and interventions? Please note, this could include translating evidence from other settings. If yes, please provide details in the comment box. |
|---|
| Only answer this question if the following conditions are met: Answer was at question '6 [HTAIG1]' (Does your country have a systematic formal process by which information is gathered to support healthcare decision-making?) |
| Please choose only one of the following: |
| Yes |
| ○ No |
| Make a comment on your choice here: |
| |
| |
| |
| |
| |
| |
| |
| |

| 13 Are there any formal or informal procedures, rules, thresholds, or laws that factor in to the decision-making related to health technologies and interventions? If yes, please provide details in the comment box. |
|---|
| Only answer this question if the following conditions are met: Answer was 'None' at question '6 [HTAIG1]' (Does your country have a systematic formal process by which information is gathered to support healthcare decision-making?) |
| Please choose only one of the following: |
| Yes |
| ○ No |
| Make a comment on your choice here: |
| |
| |
| |
| |
| |
| |
| |
| |

| 14 Are there any provisions for revising decisions about health technologies and interventions |
|---|
| once they are made? If yes, please provide details in the comment box. |
| Only answer this question if the following conditions are met: |
| Answer was 'None' at question '6 [HTAIG1]' (Does your country have a systematic formal process by which information is gathered to support healthcare decision-making?) |
| Please choose only one of the following: |
| Yes |
| ○ No |
| Make a comment on your choice here: |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| 15 For which of the following functions is information gathered in your setting? |
| Please choose all that apply: |
| Clinical practice guidelines |
| Planning and budgeting |
| Pricing/pricing negotiations of medical technologies |
| Indicators of quality of care |
| To determine objectives for pay-for-performance schemes |
| Design of Health Benefit Packages |
| Public Procurement of Medicines |
| Protocols for public health programmes |
| Other: |
| |

| Only answer this process as Health Technology Assessment (HTA)? Only answer this question if the following conditions are met: Answer was 'Yes, at the subnational level' or 'Yes, at the national level' at question '6 [HTAIG1]' (Does your country have a systematic formal process by which information is gathered to support healthcare decision-making?) Please choose only one of the following: Yes No No 17 Do you have a standard methodology or process guideline for conducting HTA or decision-making process? If yes, please provide a link to the document in the comment box or upload the document in the following question. Only answer this question if the following conditions are met: Answer was 'Yes, at the subnational level' or 'Yes, at the national level' at question '6 [HTAIG1]' (Does your country have a systematic formal process by which information is gathered to support healthcare decision-making?) Please choose only one of the following: Yes No Make a comment on your choice here: We refer to the broader HTA process and specific questions about methods for economic evaluation (e.g. cost-effectiveness) will be asked later. | |
|---|--|
| Answer was 'Yes, at the subnational level' or 'Yes, at the national level' at question '6 [HTAIG1]' (Does your country have a systematic formal process by which information is gathered to support healthcare decision-making?) Please choose only one of the following: Yes No 17 Do you have a standard methodology or process guideline for conducting HTA or decision-making process? If yes, please provide a link to the document in the comment box or upload the document in the following question. Only answer this question if the following conditions are met: Answer was 'Yes, at the subnational level' or 'Yes, at the national level' at question '6 [HTAIG1]' (Does your country have a systematic formal process by which information is gathered to support healthcare decision-making?) Please choose only one of the following: Yes No Make a comment on your choice here: We refer to the broader HTA process and specific questions about methods for economic | 16 Do you refer to this process as Health Technology Assessment (HTA)? |
| Yes No No No No No 17 Do you have a standard methodology or process guideline for conducting HTA or decision-making process? If yes, please provide a link to the document in the comment box or upload the document in the following question. Only answer this question if the following conditions are met: Answer was 'Yes, at the subnational level' or 'Yes, at the national level' at question '6 [HTAIG1]' (Does your country have a systematic formal process by which information is gathered to support healthcare decision-making?) Please choose only one of the following: Yes No Make a comment on your choice here: We refer to the broader HTA process and specific questions about methods for economic | Answer was 'Yes, at the subnational level' <i>or</i> 'Yes, at the national level' at question '6 [HTAIG1]' (Does your country have a systematic formal process by which information is |
| 17 Do you have a standard methodology or process guideline for conducting HTA or decision-making process? If yes, please provide a link to the document in the comment box or upload the document in the following question. Only answer this question if the following conditions are met: Answer was 'Yes, at the subnational level' or 'Yes, at the national level' at question '6 [HTAIG1]' (Does your country have a systematic formal process by which information is gathered to support healthcare decision-making?) Please choose only one of the following: Yes No Make a comment on your choice here: We refer to the broader HTA process and specific questions about methods for economic | Please choose only one of the following: |
| 17 Do you have a standard methodology or process guideline for conducting HTA or decision-making process? If yes, please provide a link to the document in the comment box or upload the document in the following question. Only answer this question if the following conditions are met: Answer was 'Yes, at the subnational level' or 'Yes, at the national level' at question '6 [HTAIG1]' (Does your country have a systematic formal process by which information is gathered to support healthcare decision-making?) Please choose only one of the following: Yes No Make a comment on your choice here: We refer to the broader HTA process and specific questions about methods for economic | Yes |
| decision-making process? If yes, please provide a link to the document in the comment box or upload the document in the following question. Only answer this question if the following conditions are met: Answer was 'Yes, at the subnational level' or 'Yes, at the national level' at question '6 [HTAIG1]' (Does your country have a systematic formal process by which information is gathered to support healthcare decision-making?) Please choose only one of the following: Yes No Make a comment on your choice here: We refer to the broader HTA process and specific questions about methods for economic | ○ No |
| decision-making process? If yes, please provide a link to the document in the comment box or upload the document in the following question. Only answer this question if the following conditions are met: Answer was 'Yes, at the subnational level' or 'Yes, at the national level' at question '6 [HTAIG1]' (Does your country have a systematic formal process by which information is gathered to support healthcare decision-making?) Please choose only one of the following: Yes No Make a comment on your choice here: We refer to the broader HTA process and specific questions about methods for economic | |
| Answer was 'Yes, at the subnational level' or 'Yes, at the national level' at question '6 [HTAIG1]' (Does your country have a systematic formal process by which information is gathered to support healthcare decision-making?) Please choose only one of the following: Yes No Make a comment on your choice here: We refer to the broader HTA process and specific questions about methods for economic | decision-making process? If yes, please provide a link to the document in the comment box or |
| Yes No Make a comment on your choice here: We refer to the broader HTA process and specific questions about methods for economic | Answer was 'Yes, at the subnational level' <i>or</i> 'Yes, at the national level' at question '6 [HTAIG1]' (Does your country have a systematic formal process by which information is |
| No Make a comment on your choice here: We refer to the broader HTA process and specific questions about methods for economic | Please choose only one of the following: |
| Make a comment on your choice here: We refer to the broader HTA process and specific questions about methods for economic | Yes |
| We refer to the broader HTA process and specific questions about methods for economic | ○ No |
| | Make a comment on your choice here: |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| evaluation (e.g. cost-effectiveness) will be asked later. | |
| | evaluation (e.g. cost-effectiveness) will be asked later. |

18 If possible, please upload the standard HTA methodology/guidance document here.

Only answer this question if the following conditions are met:

Answer was 'Yes' at question '17 [HTAIG4a]' (Do you have a standard methodology or process guideline for conducting HTA or decision-making process? If yes, please provide a link to the document in the comment box or upload the document in the following question.)

Kindly attach the aforementioned documents along with the survey

19

For each of the following areas of the HTA or decision-making process, please list the organisation(s) or entity(ies) responsible for the components of assessment, appraisal and recommendation for each category of interventions?

Only answer this question if the following conditions are met:

Answer was 'Yes, at the national level' *or* 'Yes, at the subnational level' at question '6 [HTAIG1]' (Does your country have a systematic formal process by which information is gathered to support healthcare decision-making?)

| | Pharmace Medicines | Medical Procedure | Medical Devices | Diagnostic Tests | Population Level Health Interventions |
|---------------------------|-----------------------|----------------------|--------------------|---------------------|--|
| Assessment (Data) | | | | | |
| Appraisal (Dialogue) | | | | | |
| Recommendation (Decision) | | | | | |

Please add multiple entities to each box as needed.

Population Level Health Interventions - (i.e. large scale screening/vaccination programs)

| 20 Is there a legislative and/or regulatory requirement to consider the results of HTA or decision-making process while making coverage decisions or inclusion of an intervention in the health benefits package? Only answer this question if the following conditions are met: Answer was 'Yes, at the subnational level' or 'Yes, at the national level' at question '6 [HTAIG1]' (Does your country have a systematic formal process by which information is |
|--|
| gathered to support healthcare decision-making?) |
| Please choose only one of the following: |
| Yes |
| ○ No |
| O I don't know |
| |
| 21 Please specify the institutional mechanisms (e.g. law, or regulation) and/or provide a link to the appropriate document. |
| You may also upload any relevant documents in the following question. |
| Only answer this question if the following conditions are met: Answer was 'Yes' at question '20 [HTAIG5]' (Is there a legislative and/or regulatory requirement to consider the results of HTA or decision-making process while making coverage decisions or inclusion of an intervention in the health benefits package?) |
| Please write your answer here: |
| |
| |

22 Please upload any relevant documents if you wish to do so

Only answer this question if the following conditions are met:

Answer was 'Yes' at question '20 [HTAIG5]' (Is there a legislative and/or regulatory requirement to consider the results of HTA or decision-making process while making coverage decisions or inclusion of an intervention in the health benefits package?)

Kindly attach the aforementioned documents along with the survey

| 23 |
|--|
| Are the results of the HTA or decision-making process considered binding by law? |
| Only answer this question if the following conditions are met: Answer was 'Yes' at question '20 [HTAIG5]' (Is there a legislative and/or regulatory requirement to consider the results of HTA or decision-making process while making coverage decisions or inclusion of an intervention in the health benefits package?) |
| Please choose only one of the following: |
| YesNoI don't know |
| 24 Has your organization formally collaborated with or is it currently collaborating with other organizations on the HTA or decision-making process? |
| Please choose only one of the following: |
| Yes, with organizations within our country |
| Yes, with organization from other countries |
| Both |
| ○ No |
| *Formal Collaboration |

| 25 Which kind of organizations from YOUR COUNTRY have you been collaborating with? |
|--|
| Only answer this question if the following conditions are met: Answer was 'Yes, with organizations within our country' <i>or</i> 'Both' at question '24 [HTAIG10]' (Has your organization formally collaborated with or is it currently collaborating with other organizations on the HTA or decision-making process?) |
| Please choose all that apply and provide a comment: |
| Ministries or other Government Institutions |
| |
| Academia/University |
| |
| Professional associations |
| Hospital |
| |
| Industry |
| |
| Patient Associations |
| Other places enecify |
| Other, please specify |
| Please refer to only formal collaborations Please give name/details of the Organisation(s) that you select If you have a website with a list of institutions, please provide the link in the Other box You can select multiple options |

| 26 Which kind of organizations from OTHER COUNTRIES have you been collaborating with? |
|--|
| Only answer this question if the following conditions are met: Answer was 'Both' <i>or</i> 'Yes, with organization from other countries' at question '24 [HTAIG10]' (Has your organization formally collaborated with or is it currently collaborating with other organizations on the HTA or decision-making process?) |
| Please choose all that apply and provide a comment: |
| Ministries or other Government Institutions |
| Academia/University |
| Professional associations |
| Hospital |
| Industry |
| Patient Associations |
| Other, please specify |
| Please refer to only formal collaborations Please give name/details of the Organisation(s) that you select If you have a website with a list of institutions, please provide the link in the Other box You can select multiple options |

| Answe | Inswer this question if the following conditions are met: er was 'Yes, at the national level' or 'Yes, at the subnational level' at question '6 G1]' (Does your country have a systematic formal process by which information is red to support healthcare decision-making?) |
|--------|---|
| Please | e choose all that apply: |
| S | cientific Committee of the HTA or decision-making body |
| E | recutive Board of the HTA or decision-making body |
| D | rector of the HTA or decision-making body |
| D | epartment/Ministry of Health |
| N | ational Health Service |
| P | atient Organizations |
| С | vil Society |
| Ot | her: |
| Pleas | e specify the entity in the box if selecting Other |

| 28 Does your HTA or decision-making process include mechanisms for translation and/or contextualization of evidence from other settings? If Yes, can you please describe this process further in the comment box? |
|---|
| Please choose only one of the following: |
| Yes |
| ○ No |
| Make a comment on your choice here: |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| 29 Does your HTA or health decision-making process include any provisions for rapidly assessing evidence, appraising evidence, and making decisions in a non-emergency context? |
| Please choose only one of the following: |
| Yes |
| ○ No |
| |

| 30 Can you please describe what criteria are used to qualify something for this "rapid" process? |
|---|
| Only answer this question if the following conditions are met: Answer was 'Yes' at question '29 [HTAA5]' (Does your HTA or health decision-making process include any provisions for rapidly assessing evidence, appraising evidence, and making decisions in a non-emergency context?) |
| Please write your answer here: |
| |
| 31 Could you please describe this process further in terms of the evidence used for the appraisal and recommendation processes? |
| Only answer this question if the following conditions are met: Answer was 'Yes' at question '29 [HTAA5]' (Does your HTA or health decision-making process include any provisions for rapidly assessing evidence, appraising evidence, and making decisions in a non-emergency context?) |
| Please write your answer here: |
| |
| |
| 32 Does your HTA or health decision-making process include any provisions for rapidly assessing evidence, appraising evidence, and making decisions in the case of a disaster or emergency (e.g. Covid-19 pandemic)? |
| Please choose only one of the following: |
| |
| |

| 33 Can you please describe this process further? |
|---|
| Only answer this question if the following conditions are met: Answer was 'Yes' at question '32 [HTAA6]' (Does your HTA or health decision-making process include any provisions for rapidly assessing evidence, appraising evidence, and making decisions in the case of a disaster or emergency (e.g. Covid-19 pandemic)?) |
| Please write your answer here: |
| |
| |
| 34 Does your HTA or decision-making body include indicators to assess the impact of its own products? |
| Only answer this question if the following conditions are met: |
| Answer was 'Yes, at the subnational level' <i>or</i> 'Yes, at the national level' at question '6 [HTAIG1]' (Does your country have a systematic formal process by which information is gathered to support healthcare decision-making?) |
| Please choose only one of the following: |
| Yes |
| ○ No |

| 35 Which of the following criteria are used by your organization to assess the impact of its recommendations? | |
|---|--|
| Only answer this question if the following conditions are met: Answer was 'Yes' at question '34 [HTAIG13]' (Does your HTA or decision-making body include indicators to assess the impact of its own products?) | |
| Please choose all that apply: | |
| Changes within organization or facilities (training staff, buying materials, etc.) | |
| Variation in practice before and after recommendation | |
| Variation between current practice and recommended practice over time | |
| Level of technology diffusion over time | |
| Change in health outcomes over time (clinical changes) | |
| Changes in the cost of the medical practice over time | |
| Changes in the law | |
| Changes in health from the point of view of the patients (perceived health, | |
| satisfaction, others) | |
| Other: | |
| | |
| You can select multiple options | |
| | |
| ITA Available Resources | |
| he section below asks about resources available for HTA and health care decisonaking in your country. Please answer with regards to the organization(s)/entity(ies) ou have referenced above. | |
| 36 Does the HTA or decision making body/bodies in your setting have an allocated budget | |
| from the public sector? | |
| Please choose only one of the following: | |
| Yes | |
| ○ No | |
| O I don't know | |

| 37 From the | overall budget, are any resources received through PRIVATE funding? |
|--|--|
| Please choo | se only one of the following: |
| Yes | |
| | ata Constina |
| O No Priva | ate Funding |
| | |
| 38 What pe | centage of the overall budget is received through Private Funding? |
| Only answe | r this question if the following conditions are met: |
| | 'Yes' at question '37 [HTAIG9]' (From the overall budget, are any eceived through PRIVATE funding?) |
| | G , |
| | your answer(s) here: |
| Percentage | of Private Funding |
| | |
| | |
| 39 Out of th | e percentage provided above, please select the different sources of sposorship |
| funding rece Only answe Answer was | e percentage provided above, please select the different sources of sposorship ived by your organization from the following categories of PRIVATE institutions? In this question if the following conditions are met: 'Yes' at question '37 [HTAIG9]' (From the overall budget, are any exceived through PRIVATE funding?) |
| Only answer was resources re | ived by your organization from the following categories of PRIVATE institutions? This question if the following conditions are met: 'Yes' at question '37 [HTAIG9]' (From the overall budget, are any |
| Only answer was resources re | ived by your organization from the following categories of PRIVATE institutions? If this question if the following conditions are met: I'Yes' at question '37 [HTAIG9]' (From the overall budget, are any exceived through PRIVATE funding?) I see all that apply: |
| Only answer was resources replease choo | ived by your organization from the following categories of PRIVATE institutions? If this question if the following conditions are met: I'Yes' at question '37 [HTAIG9]' (From the overall budget, are any exceived through PRIVATE funding?) I see all that apply: |
| Only answer was resources replease chool Industry | ived by your organization from the following categories of PRIVATE institutions? If this question if the following conditions are met: I'Yes' at question '37 [HTAIG9]' (From the overall budget, are any exceived through PRIVATE funding?) I see all that apply: |
| Only answer was resources replease chool Industry Research | ived by your organization from the following categories of PRIVATE institutions? If this question if the following conditions are met: I'Yes' at question '37 [HTAIG9]' (From the overall budget, are any exceived through PRIVATE funding?) I see all that apply: I should be apply: I should be a should be |
| Only answer was resources replease chool Industry Research | r this question if the following conditions are met: 'Yes' at question '37 [HTAIG9]' (From the overall budget, are any eceived through PRIVATE funding?) see all that apply: ch funding bodies care providers nia/University |
| Only answer Answer was resources replease chooses and the latest a | r this question if the following conditions are met: 'Yes' at question '37 [HTAIG9]' (From the overall budget, are any eceived through PRIVATE funding?) see all that apply: ch funding bodies care providers nia/University |
| Only answer Answer was resources replease choosed industry Research Academ Donor Academ Medical | r this question if the following conditions are met: 'Yes' at question '37 [HTAIG9]' (From the overall budget, are any eceived through PRIVATE funding?) see all that apply: ch funding bodies care providers nia/University agency |
| Only answer Answer was resources replease choosed industry Research Academ Donor Academ Other: | ived by your organization from the following categories of PRIVATE institutions? In this question if the following conditions are met: 'Yes' at question '37 [HTAIG9]' (From the overall budget, are any exceived through PRIVATE funding?) In the funding bodies In the funding |
| Only answer was resources | r this question if the following conditions are met: 'Yes' at question '37 [HTAIG9]' (From the overall budget, are any exceived through PRIVATE funding?) see all that apply: ch funding bodies care providers nia/University sgency Insurance Insurance Insurance Insurance Insurance given source, please check the |
| Only answer Answer was resources replease choosed and the second a | r this question if the following conditions are met: 'Yes' at question '37 [HTAIG9]' (From the overall budget, are any exceived through PRIVATE funding?) see all that apply: ch funding bodies care providers nia/University sgency Insurance Insurance Insurance Insurance Insurance given source, please check the |

| 40 How are the commissions/committees of the HTA or decision-making body funded? |
|--|
| Please choose all that apply: |
| Public Budgets |
| Application Fees |
| Other: |
| 41 Please estimate the number of professional staff involved in the HTA unit/agency/committee (in full-time equivalents). Please choose only one of the following: Less than 1 1-5 6-20 21-50 51-100 >100 |

HTA Assessment (or Data)

The following questions refer to the "Assessment" process of HTA, also linked to "Data" in the 3Ds decision framework. Assessment is defined as: A scientific process used to describe and analyse the properties of a health technology—its safety, efficacy, feasibility and indications for use, cost and cost-effectiveness, as well as social, economic and ethical consequences. Please answer the following questions with regards to this specific process. The assessment process normally consists of evidence collection, analysis of the quality of the evidence, synthesizing the evidence, and reporting the findings and implications.

| 42 How long does the assessment process take on average for any given health intervention or technology? Please choose only one of the following: |
|--|
| <1 month 1-3 months 3-6 month 6-12 months |
| >1 year |
| 43 In the last 12 months, approximately, how many assessments were performed? Please write your answer here: |

| | Number of Assessments |
|---------------------------------------|---|
| harmaceuticals/Medicine | |
| edical Procedure | |
| edical devices | |
| iagnostic Tests | |
| opulation Level Health terventions | |
| thers (Please Specify) | |
| the best degree possible | , the total should match the answer provided in |
| pulation Level Health Inte ograms) | erventions(i.e. large scale screening/vaccination |
| | |

HTA Appraisal (or Dialogue)

The following questions refer to the "Appraisal" process of HTA, also linked to "Dialogue" in the 3Ds decision framework. In the Appraisal phase, the evidence that is provided from the previous assessment is scrutinized and deliberated on. Please answer the following questions with regards to this specific process. In the appraisal step, the HTA organization interprets the results of the assessment and formulates a recommendation or guidance to inform decision makers.

| 46 Please list which of the following aspects are covered in the appraisal phase for | the |
|--|-----|
| categories of interventions? | |

| | Pharmace: Medicines | Medical Procedure | Medical Devices | Diagnostic Tests | Population Level Health Interventions |
|--|------------------------|----------------------|--------------------|---------------------|--|
| Safety | | | | | |
| Clinical effectiveness | | | | | |
| Cost-Effectiveness Analysis (Economic Evaluations) | | | | | |
| Budget Impact Analysis | | | | | |
| Equity issues (e.g. Socioeconomic considerations, Gender) | | | | | |
| Severity of Illness | | | | | |
| Financial Risk Protection | | | | | |
| Other Ethical issues | | | | | |
| Feasibility (e.g. availability of budget and human resources) | | | | | |
| Acceptability to providers | | | | | |
| Acceptability to patients | | | | | |
| Others (Please Specify) | | | | | |

Population Level Health Interventions - i.e. large scale screening/vaccination programs

| 47 Other 1 |
|--|
| Please write your answer here: |
| |
| |
| |
| |
| 48 Are there national guidelines for the preparation of economic evaluations? |
| Please choose only one of the following: |
| Yes, Please provide a link in the box or upload a file in the next question |
| No |
| |
| Make a comment on your choice here: |
| |
| |
| |
| |
| |
| |
| |
| |
| If yes, please provide a link in the box or upload a file in the next question (an upload button |
| will appear once you click yes here) |
| |
| |
| 49 If necessary, please upload a file of national guidelines for the preparation of economic |
| evaluations |
| Only answer this question if the following conditions are met: |
| Answer was 'Yes, Please provide a link in the box or upload a file in the next question' at |
| question '48 [HTAA1a]' (Are there national guidelines for the preparation of economic |
| evaluations?) |

Kindly attach the aforementioned documents along with the survey

| 50 Are there other relevant guidelines for the preparation of evidence for the appraisal process? |
|---|
| Please choose only one of the following: |
| Yes, Please provide a link in the box or upload a file in the next question No |
| Make a comment on your choice here: |
| If yes, please provide a link in the box or upload a file in the next question (an upload button will appear once you click yes here) |
| |
| |

51 If necessary, please upload a file of other relevant guidelines for the preparation of evidence

Only answer this question if the following conditions are met:

Answer was 'Yes, Please provide a link in the box or upload a file in the next question' at question '50 [HTAA1]' (Are there other relevant guidelines for the preparation of evidence for the appraisal process?)

Kindly attach the aforementioned documents along with the survey

| 52 Does your country have a public and updated database of health technology costs or prices? | | | | |
|--|--|--|--|--|
| Please choose only one of the following: | | | | |
| Yes, Please provide a link in the box or upload a file in the next question No | | | | |
| Make a comment on your choice here: | | | | |
| | | | | |
| If yes, please provide a link in the box or upload a file in the next question (an upload button will appear once you click yes here) | | | | |
| 53 If necessary, please upload a file of your database of health technology costs or prices | | | | |
| Only answer this question if the following conditions are met: | | | | |
| Answer was 'Yes, Please provide a link in the box or upload a file in the next question' at question '52 [HTAIG11]' (Does your country have a public and updated database of health technology costs or prices?) | | | | |
| Kindly attach the aforementioned documents along with the survey | | | | |
| If cost-effectiveness or cost-utility analysis is used for decision-making (i.e. if an incremental cost effectiveness ratio is computed), is there an officially endorsed threshold used to assess whether a new procedure, a new medicine, or a new device will be funded? Please choose only one of the following: Yes No | | | | |

| 55 |
|---|
| Does the threshold vary across different categories of patients, diseases or interventions? |
| Only answer this question if the following conditions are met: Answer was 'Yes' at question '54 [HTAR7]' (If cost-effectiveness or cost-utility analysis is used for decision-making (i.e. if an incremental cost effectiveness ratio is computed), is there an officially endorsed threshold used to assess whether a new procedure, a new medicine, or a new device will be funded?) |
| Please choose only one of the following: |
| Yes No No |
| |
| 56 What is the basis for the variation? |
| Only answer this question if the following conditions are met: Answer was 'Yes' at question '55 [HTAR7a]' (Does the threshold vary across different categories of patients, diseases or interventions?) |
| Please write your answer here: |
| |

| 57 | |
|--|----------------|
| Please specify the cost-effectiveness threshold(s) used. Also, please specify sthreshold(s) have been in use and how often are they reviewed. | since when the |
| Only answer this question if the following conditions are met: Answer was 'Yes' at question '54 [HTAR7]' (If cost-effectiveness or cost-used for decision-making (i.e. if an incremental cost effectiveness ratio is there an officially endorsed threshold used to assess whether a new proceeding, or a new device will be funded?) | computed), is |
| Please write your answer here: | |
| | |
| 58 Please explain the rationale for using this threshold value in your country. Only answer this question if the following conditions are met: | ? |
| Answer was 'Yes' at question '54 [HTAR7]' (If cost-effectiveness or cost-used for decision-making (i.e. if an incremental cost effectiveness ratio is there an officially endorsed threshold used to assess whether a new proceeding, or a new device will be funded?) | computed), is |
| Please write your answer here: | |
| | |
| | the comment |

59 If necessary, please upload a file of explaining the rationale for using specific values for cost-effectiveness.

Only answer this question if the following conditions are met:

Answer was 'Yes' at question '54 [HTAR7]' (If cost-effectiveness or cost-utility analysis is used for decision-making (i.e. if an incremental cost effectiveness ratio is computed), is there an officially endorsed threshold used to assess whether a new procedure, a new medicine, or a new device will be funded?)

Kindly attach the aforementioned documents along with the survey

| 60 Please fill in the following table regarding the appraisal organization for each category | of |
|--|----|
| health intervention. | |

| | Who appoints the members of each appraisal commission/committee? | How often does each appraisal commission/committee meet? |
|--|--|--|
| Pharmaceuticals/Medicine | | |
| Medical Procedures | | |
| Medical Devices | | |
| Diagnostic Tests | | |
| Population Level Health Interventions(i.e. large scale screening/vaccination programs) | | |
| Others(Please Specify) | | |

Kindly refer back to the organizations that you mentioned in question 19 of the Institutions and Governance section.

| 61 Other | |
|--------------------------------|--|
| Please write your answer here: | |
| | |
| | |

62 Which of the stakeholders below (see table) are represented in the body (Commission, Committee, etc.) responsible for the appraisal of applications?

| | Pharmace: / Medicine | Medical Procedure | Medical Device | Diagnostic Tests | Population Level Health Intervention |
|--|----------------------|----------------------|-------------------|---------------------|---|
| Medical professionals (doctors, pharmacists, dentists) | | | | | |
| Public health specialists, epidemiologists | | | | | |
| Statisticians | | | | | |
| Economists | | | | | |
| Specialists in social science (ethics, philosophy, etc.) | | | | | |
| Government | | | | | |
| Social health insurance | | | | | |
| Private insurers | | | | | |
| Medical association/chamber | | | | | |
| Medical Union | | | | | |
| Hospital association | | | | | |
| Pharma/medical industry | | | | | |
| Patient association | | | | | |
| Consumer association | | | | | |
| Representative of citizens | | | | | |

| | Pharmacei / Medicine | Medical Procedure | Medical Device | Diagnostic Tests | Population Level Health Interventions |
|--|-------------------------|----------------------|-------------------|---------------------|--|
| Vulnerable and marginalized groups (e.g. religious minorities, migrants, rural populations, women's' groups, youth groups etc) | | | | | |
| Other members | | | | | |
| Population Level Health Inter | ventions - i.e. la | rge scale scree | ening/vaccina | tion programs | |
| | | rge scale scree | ening/vaccina | tion programs | |
| 3 Other | here: represented ir | n these bodies | have equal | | ppraisal |
| 63 Other Please write your answer 64 Do all the stakeholders process (e.g. by vote, alloca | here: represented ir | n these bodies | have equal | | ppraisal |

65 Which of the following are the stakeholders who have less voice in the appraisal process (e.g. by less voting power, allocated time, or other mode of input)?

Only answer this question if the following conditions are met: Answer was 'No' at question '64 [HTAAP1c]' (Do all the stakeholders represented in these bodies have equal voice in the appraisal process (e.g. by vote, allocated time, or other mode of input)?)

Please choose the appropriate response for each item:

| | Have less voice |
|--|-----------------|
| Medical professionals (doctors, pharmacists, dentists) | |
| Public health specialists, epidemiologists | |
| Statisticians | |
| Economists | |
| Specialists in social science (ethics, philosophy, etc.) | |
| Government | |
| Social health insurance | |
| Private insurers | |
| Medical association/chamber | |
| Medical Union | |
| Hospital association | |
| Pharma/medical industry | |
| Patient association | |
| Consumer association | |
| Representative of citizens | |

| Vulnerable and marginalized groups (e.g. religious minorities, migrants, rural populations, women's' groups, youth groups etc) Other members: 66 Are stakeholders not represented in the body responsible for the appraisal of applications invited to react/comment during the whole process? Please choose only one of the following: Yes No 67 Referring to the question above, How is this done? Only answer this question if the following conditions are met: Answer was 'Yes' at question '66 [HTAAP1e]' (Are stakeholders not represented in the body responsible for the appraisal of applications invited to react/comment during the whole process?) Please choose all that apply: Through public consultations Through specific hearings Through online submissions | vuinerable and | _ |
|--|---|--|
| minorities, migrants, rural populations, women's' groups, youth groups etc) Other members: 66 Are stakeholders not represented in the body responsible for the appraisal of applications invited to react/comment during the whole process? Please choose only one of the following: Yes No 67 Referring to the question above, How is this done? Only answer this question if the following conditions are met: Answer was "Yes' at question '66 [HTAAP1e]" (Are stakeholders not represented in the body responsible for the appraisal of applications invited to react/comment during the whole process?) Please choose all that apply: Through public consultations Through specific hearings Through online submissions | marginalized groups | |
| women's' groups, youth groups etc) Other members: 66 Are stakeholders not represented in the body responsible for the appraisal of applications invited to react/comment during the whole process? Please choose only one of the following: Yes No No 67 Referring to the question above, How is this done? Only answer this question if the following conditions are met: Answer was 'Yes' at question '66 [HTAAP1e]' (Are stakeholders not represented in the body responsible for the appraisal of applications invited to react/comment during the whole process?) Please choose all that apply: Through public consultations Through specific hearings Through online submissions | , , | |
| youth groups etc) Other members: 66 Are stakeholders not represented in the body responsible for the appraisal of applications invited to react/comment during the whole process? Please choose only one of the following: Yes No No 67 Referring to the question above, How is this done? Only answer this question if the following conditions are met: Answer was 'Yes' at question '66 [HTAAP1e]' (Are stakeholders not represented in the body responsible for the appraisal of applications invited to react/comment during the whole process?) Please choose all that apply: Through public consultations Through specific hearings Through online submissions | | |
| 66 Are stakeholders not represented in the body responsible for the appraisal of applications invited to react/comment during the whole process? Please choose only one of the following: Yes No No 67 Referring to the question above, How is this done? Only answer this question if the following conditions are met: Answer was 'Yes' at question '66 [HTAAP1e]' (Are stakeholders not represented in the body responsible for the appraisal of applications invited to react/comment during the whole process?) Please choose all that apply: Through public consultations Through specific hearings Through online submissions | | |
| invited to react/comment during the whole process? Please choose only one of the following: Yes No No Referring to the question above, How is this done? Only answer this question if the following conditions are met: Answer was 'Yes' at question '66 [HTAAP1e]' (Are stakeholders not represented in the body responsible for the appraisal of applications invited to react/comment during the whole process?) Please choose all that apply: Through public consultations Through specific hearings Through online submissions | Other members: | |
| invited to react/comment during the whole process? Please choose only one of the following: Yes No No Referring to the question above, How is this done? Only answer this question if the following conditions are met: Answer was 'Yes' at question '66 [HTAAP1e]' (Are stakeholders not represented in the body responsible for the appraisal of applications invited to react/comment during the whole process?) Please choose all that apply: Through public consultations Through specific hearings Through online submissions | 66 Are stakeholders not re | presented in the body responsible for the appraisal of applications |
| Yes No No Referring to the question above, How is this done? Only answer this question if the following conditions are met: Answer was 'Yes' at question '66 [HTAAP1e]' (Are stakeholders not represented in the body responsible for the appraisal of applications invited to react/comment during the whole process?) Please choose all that apply: Through public consultations Through specific hearings Through online submissions | invited to react/comment du | ring the whole process? |
| 67 Referring to the question above, How is this done? Only answer this question if the following conditions are met: Answer was 'Yes' at question '66 [HTAAP1e]' (Are stakeholders not represented in the body responsible for the appraisal of applications invited to react/comment during the whole process?) Please choose all that apply: Through public consultations Through specific hearings Through online submissions | Please choose only one of | of the following: |
| 67 Referring to the question above, How is this done? Only answer this question if the following conditions are met: Answer was 'Yes' at question '66 [HTAAP1e]' (Are stakeholders not represented in the body responsible for the appraisal of applications invited to react/comment during the whole process?) Please choose all that apply: Through public consultations Through specific hearings Through online submissions | Yes | |
| Referring to the question above, How is this done? Only answer this question if the following conditions are met: Answer was 'Yes' at question '66 [HTAAP1e]' (Are stakeholders not represented in the body responsible for the appraisal of applications invited to react/comment during the whole process?) Please choose all that apply: Through public consultations Through specific hearings Through online submissions | ○ No | |
| Referring to the question above, How is this done? Only answer this question if the following conditions are met: Answer was 'Yes' at question '66 [HTAAP1e]' (Are stakeholders not represented in the body responsible for the appraisal of applications invited to react/comment during the whole process?) Please choose all that apply: Through public consultations Through specific hearings Through online submissions | | |
| Referring to the question above, How is this done? Only answer this question if the following conditions are met: Answer was 'Yes' at question '66 [HTAAP1e]' (Are stakeholders not represented in the body responsible for the appraisal of applications invited to react/comment during the whole process?) Please choose all that apply: Through public consultations Through specific hearings Through online submissions | | |
| Only answer this question if the following conditions are met: Answer was 'Yes' at question '66 [HTAAP1e]' (Are stakeholders not represented in the body responsible for the appraisal of applications invited to react/comment during the whole process?) Please choose all that apply: Through public consultations Through specific hearings Through online submissions | | |
| Answer was 'Yes' at question '66 [HTAAP1e]' (Are stakeholders not represented in the body responsible for the appraisal of applications invited to react/comment during the whole process?) Please choose all that apply: Through public consultations Through specific hearings Through online submissions | | ova How is this done? |
| whole process?) Please choose all that apply: Through public consultations Through specific hearings Through online submissions | Referring to the question ab | |
| Please choose all that apply: Through public consultations Through specific hearings Through online submissions | Referring to the question about the control of the | if the following conditions are met: ion '66 [HTAAP1e]' (Are stakeholders not represented in the |
| Through public consultations Through specific hearings Through online submissions | Referring to the question about the control of the | if the following conditions are met: ion '66 [HTAAP1e]' (Are stakeholders not represented in the |
| Through specific hearings Through online submissions | Referring to the question about Only answer this question Answer was 'Yes' at quest body responsible for the a whole process? | if the following conditions are met: ion '66 [HTAAP1e]' (Are stakeholders not represented in the ppraisal of applications invited to react/comment during the |
| Through online submissions | Referring to the question about Only answer this question Answer was 'Yes' at quest body responsible for the a whole process?) Please choose all that app | if the following conditions are met: ion '66 [HTAAP1e]' (Are stakeholders not represented in the ppraisal of applications invited to react/comment during the oly: |
| | Referring to the question about Only answer this question Answer was 'Yes' at quest body responsible for the a whole process?) Please choose all that appure Through public consu | if the following conditions are met: ion '66 [HTAAP1e]' (Are stakeholders not represented in the ppraisal of applications invited to react/comment during the oly: tations |
| Other: | Referring to the question about the consumer of the question and the consumer of the consumer | if the following conditions are met: ion '66 [HTAAP1e]' (Are stakeholders not represented in the ppraisal of applications invited to react/comment during the oly: tations |
| | Referring to the question about the consumer of the question and the consumer of the consumer | if the following conditions are met: ion '66 [HTAAP1e]' (Are stakeholders not represented in the ppraisal of applications invited to react/comment during the oly: tations |

previous section.

| /16/2020 | DataForm Extranet - Health Technology Assessment/Health Benefit Package Survey 2020 |
|--|---|
| 68 Are mei | mbers of the appraisal body required to provide a declaration of conflict of |
| Please cho | oose only one of the following: |
| Yes | |
| ○ No | |
| HTA Reco | ommendation (or Decision) |
| The following q the 3Ds decisio | ommendation (or Decision) uestions refer to the "Recommendation" process of HTA, also linked to "Decision" in n framework. In this phase, recommendations are developed based on the appraisal. the following questions with regards to this specific phase. |
| The following q the 3Ds decisio Please answer 69 Is there | uestions refer to the "Recommendation" process of HTA, also linked to "Decision" in n framework. In this phase, recommendations are developed based on the appraisal. |
| The following q the 3Ds decisio Please answer 69 Is there the appraisa | uestions refer to the "Recommendation" process of HTA, also linked to "Decision" in n framework. In this phase, recommendations are developed based on the appraisal. the following questions with regards to this specific phase. a separate committee or entity responsible for recommendation (or decision) after |
| The following q the 3Ds decisio Please answer 69 Is there the appraisa | uestions refer to the "Recommendation" process of HTA, also linked to "Decision" in n framework. In this phase, recommendations are developed based on the appraisal. the following questions with regards to this specific phase. a separate committee or entity responsible for recommendation (or decision) after all process has been conducted? * |

It is possible for the appraisal committee to have a decision role as well - If that is the case in your setting please select No as we have already asked questions about this entity in the

| _ | - | _ |
|---|---|---|
| 7 | 1 | ٦ |
| • | ı | |

Please fill in the following table regarding the recommendation process for each category of health intervention.

Only answer this question if the following conditions are met:

Answer was 'Yes' at question '69 [HTAAP1]' (Is there a separate committee or entity

| conducted?) | ion (or decision) after the appraisal process has been |
|--|---|
| | Who appoints the members of each commission/committee involved in the recommendation process? |
| Pharmaceuticals / Medicines | |
| Medical Procedures | |
| Medical Devices | |
| Diagnostic Tests | |
| Population Level Health Interventions(i.e. large scale screening/vaccination programs) | |
| Others(Please Specify) | |
| Kindly refer back to the organiz Governance section. | ation that you mentioned in question 19 of the Institutions and |
| 71 OtherHTAR1aa | |
| Please write your answer here | e: |
| | |

72 Which of the stakeholders below are represented in the body (Commission, Committee, etc.) which provides the final decision?

Only answer this question if the following conditions are met:

Answer was 'Yes' at question '69 [HTAAP1]' (Is there a separate committee or entity responsible for recommendation (or decision) after the appraisal process has been conducted?)

| | Pharmace: Medicine | Medical Procedure | Medical Device | Diagnostic Tests | Population Level Health Intervention |
|--|-----------------------|----------------------|-------------------|---------------------|---|
| Medical professionals (doctors, pharmacists, dentists) | | | | | |
| Public health specialists, epidemiologists | | | | | |
| Statisticians | | | | | |
| Economists | | | | | |
| Specialists in social science (ethics, philosophy, etc.) | | | | | |
| Government | | | | | |
| Social health insurance | | | | | |
| Private insurers | | | | | |
| Medical association/chamber | | | | | |
| Medical Union | | | | | |
| Hospital association | | | | | |
| Pharma/medical industry | | | | | |
| Patient association | | | | | |
| Consumer association | | | | | |
| Representative of citizens | | | | | |

| DataForm Extranet - Health | T | A +/ + - | Danasit Daaltana | C |
|----------------------------|------------|-------------------|------------------|-------------|
| DaiaForm Extranet - Healin | Technology | Accecement/Health | Benefii Package | SHIVEV ZUZI |
| | | | | |

10/16/2020

| | Pharmace: Medicine | Medical Procedure | Medical Device | Diagnostic Tests | Population Level Health Intervention |
|--|--|--|--------------------------|---------------------|--------------------------------------|
| Vulnerable and marginalized groups (e.g. religious minorities, migrants, rural populations, women's' groups, youth groups etc) | | | | | |
| Other members | | | | | |
| Population Level Health Interven | entions - i.e. la | rge-scale scree | ening/vaccina | tion programs | |
| | | | | | |
| 73 OtherHTAR1b Please write your answer h | nere: | | | | |
| | | body required | d to provide a | a declaration o | of conflict of |
| Please write your answer h | ommendation if the followin on '69 [HTAA | ng conditions AP1]' (Is there | are met: e a separate | committee o | r entity |
| 74 Are members of the recointerest? Only answer this question Answer was 'Yes' at question responsible for recommend | ommendation if the followin on '69 [HTAA dation (or dec | ng conditions AP1]' (Is there cision) after th | are met: e a separate | committee o | r entity |
| 74 Are members of the recointerest? Only answer this question Answer was 'Yes' at questi responsible for recommend conducted?) | ommendation if the followin on '69 [HTAA dation (or dec | ng conditions AP1]' (Is there cision) after th | are met: e a separate | committee o | r entity |

| 75 Do all the stakeholders represented in these bodies have equal voice in the process (e.g. by vote, allocated time, or other mode of input)? |
|--|
| Only answer this question if the following conditions are met: Answer was 'Yes' at question '69 [HTAAP1]' (Is there a separate committee or entity responsible for recommendation (or decision) after the appraisal process has been conducted?) |
| Please choose only one of the following: |
| YesNo |

76

Which of the following are the stakeholders who have less voice in this process (e.g. by less voting power, allocated time, or other mode of input)?

Only answer this question if the following conditions are met:

Answer was 'No' at question '75 [HTAR1c]' (Do all the stakeholders represented in these bodies have equal voice in the process (e.g. by vote, allocated time, or other mode of input)?)

Please choose the appropriate response for each item:

| | Have less voice |
|--|-----------------|
| Medical professionals (doctors, pharmacists, dentists) | |
| Public health specialists, epidemiologists | |
| Statisticians | |
| Economists | |
| Specialists in social science (ethics, philosophy, etc.) | |
| Government | |
| Social health insurance | |
| Private insurers | |
| Medical association/chamber | |
| Medical Union | |
| Hospital association | |
| Pharma/medical industry | |
| Patient association | |
| Consumer association | |
| Representative of citizens | |

| Vulnerable and marginalized groups (e.g. religious minorities, migrants, rural populations, women's' groups, youth groups etc) | |
|--|---|
| Other members: | |
| | appeal against the decision? if the following conditions are met: |
| Answer was 'Yes' at quest | on '69 [HTAAP1]' (Is there a separate committee or entity dation (or decision) after the appraisal process has been |
| Please choose only one o | f the following: |
| Yes | |
| les | |
| ○ No | |
| No No | the desision be challenged? |
| No No Refore which body can | the decision be challenged? if the following conditions are met: |
| No No Refore which body can an analysis of the control of the co | |
| No No Refore which body can an analysis of the control of the co | if the following conditions are met: on '77 [HTAR4]' (Is there a possibility to appeal against the |
| No No No Refore which body can an a | if the following conditions are met: on '77 [HTAR4]' (Is there a possibility to appeal against the |
| No | if the following conditions are met: on '77 [HTAR4]' (Is there a possibility to appeal against the |
| No N | if the following conditions are met: on '77 [HTAR4]' (Is there a possibility to appeal against the |

| ΡI | 9 Are the following published and readily available? Please provide links with your answers ease choose all that apply and provide a comment: |
|---------|---|
| | Minutes of the meetings |
| | |
| | Assessment reports |
| | |
| | Recommendations (or decisions where relevant) |
| L | |
| | Rationale for the decision |
| L | 7 |
| | _Other, Please specify |
| L | No outputs from the recommendation process are published |
| | |
| _ PI | ease provide links in the box |

Barriers to Health Technology Assessment

| 80 Please select and rank, from the list below, which barriers are most prominent at the country level to the <u>use of HTA</u> (or related decision-making processes) in health care policy decision-making. The lack of: |
|--|
| Please number each box in order of preference from 1 to 6 |
| |
| Awareness/Advocacy of the importance of HTA |
| Institutionalization of HTA |
| Mandate from Policy Authority |
| Political support |
| Qualified human resources |
| Other Issues |
| Please drag or double click the options in order of priority, with the highest priority being on the top. |
| 81 Please select and rank in order of priority, from the list below, which barriers are most prominent at the level of the HTA (or related decision-making processes) organization in terms of production capabilities. The lack of: |
| Please number each box in order of preference from 1 to 5 |
| Budget availability |
| |
| Data Availability |
| Data Availability Knowledge of methods |
| |
| Knowledge of methods |

| Please num | nber each box in order of preference from 1 to 4 |
|---|---|
| | |
| | Courses/seminars/workshops |
| | Higher advection/Meeters |
| | Higher education/Masters |
| | Internal staff training sessions or workshops |
| | Other |
| DI | |
| Piease arag | or double click the options in order of priority, with the highest priority being on |
| | or double click the options in order of priority, with the highest priority being on |
| | or double click the options in order of priority, with the highest priority being on |
| | or double click the options in order of priority, with the highest priority being on |
| the top. | |
| the top. 83 Which o | or double click the options in order of priority, with the highest priority being on of the following areas would benefit most from HTA capacity building activities fron er organizations? |
| the top. 83 Which o | of the following areas would benefit most from HTA capacity building activities fron |
| 83 Which o | of the following areas would benefit most from HTA capacity building activities fron |
| 83 Which owner of the Base cho | of the following areas would benefit most from HTA capacity building activities fron er organizations? ose all that apply: |
| 83 Which of WHO or other Please cho | of the following areas would benefit most from HTA capacity building activities fron er organizations? ose all that apply: te Development |
| 83 Which of WHO or other Please cho Manda Legal F | of the following areas would benefit most from HTA capacity building activities from er organizations? ose all that apply: te Development Framework |
| 83 Which of WHO or other Please cho Manda Legal F Instituti Assess | of the following areas would benefit most from HTA capacity building activities from er organizations? ose all that apply: te Development Framework ionalization |
| 83 Which of WHO or other Please cho Manda Legal F Instituti Assess | of the following areas would benefit most from HTA capacity building activities from er organizations? ose all that apply: te Development Framework ionalization sment Methodology |
| 83 Which of WHO or other Please cho Manda Legal F Instituti Assess Apprais | of the following areas would benefit most from HTA capacity building activities from er organizations? ose all that apply: te Development Framework ionalization sment Methodology sal Process |
| 83 Which of WHO or other Please cho Manda Legal F Instituti Assess Apprais Stakeh Monitor | of the following areas would benefit most from HTA capacity building activities from er organizations? ose all that apply: te Development -ramework ionalization sment Methodology sal Process older Engagement |

| 84 If you would like describe them here. | to mention any further barriers related to HTA in your setting, please |
|---|---|
| Please write your a | nswer here: |
| | |
| | |
| | |
| f you would like to s | specify any of the "Other Issues" that may have been ranked above, please |

THIS IS THE END OF THE HEALTH TECHNOLOGY ASSESSMENT SECTION OF THE SURVEY. WE WOULD LIKE TO THANK YOU FOR TAKING VALUABLE TIME OUT TO RESPOND TO OUR DETAILED QUESTIONS. WE APPRECIATE YOUR EFFORT IN HELPING US IN THIS IMPORTANT EXERCISE.

THE FOLLOWING QUESTIONS ARE ON HEALTH BENEFIT PACKAGES. IF YOU FEEL YOU CAN RESPOND TO THE QUESTIONS, PLEASE PROCEED FURTHER. HOWEVER, IF YOU FEEL THAT ANOTEHR PERSON OR MEMBER OF YOUR TEAM MAY BE BETTER SUITED TO RESPONDING TO OUR QUESTIONS THEN, NOW WOULD BE THE TIME TO SAVE AND SHARE THIS SURVEY WITH THEM.

THANK YOU FOR YOUR TIME AND CONSIDERATION.

| 85 PLEASE TICK THE BOX TO PROCEED TO THE HEALTH BENEFIT PACKAGE SECTION. * |
|--|
| Please choose all that apply: |
| I WOULD LIKE TO PROCEED TO THE NEXT SECTION |

Health Financing System and Health Benefit Package

86

In terms of coverage, what are the five largest, in terms of population covered, government health financing schemes in your country? Please name the schemes and rank them in order of size, 1 being the largest. (Largest here refers to the scheme which has the highest total population eligible to receive services).

- Government Health Financing Schemes can include any public sector scheme for health insurance or service provision which includes coverage for groups such as the general population, public sector employees and the military.
- To the degree possible, please try to answer for schemes that cover a range of services rather than vertical schemes focussed on one disease or intervention.
- For the remainder of the survey, we would like you to reference the largest scheme when answering questions about the health benefit package (HBP) in your country or setting.
- We would be interested to obtain information for the second largest scheme in a separate set of survey responses. If you or your team are willing to answer this survey a second time, please request another token for the survey from <a href="https://
- If this is the second time you are answering this survey, please refer to the second largest scheme for the remainder of the questions.

| 87 |
|--|
| Is this a national or a subnational level scheme? |
| Please choose only one of the following: |
| ○ National○ Subnational |
| Subnational Scheme refers to a regional or state level scheme |
| |
| 88 What percentage of the national or associated subnational population does the above scheme cover? |
| Please write your answer(s) here: |
| Largest scheme as listed above |

| 89 | | | | |
|---|--|--|--|--|
| How is coverage determined for the scheme above? Please select the most appropriate option(s). | | | | |
| Please choose all that apply: | | | | |
| Automatic coverage (e.g. based on residence) | | | | |
| Compulsory/mandatory coverage, linked to the payment of a specific contribution/premium (by individuals, households or on their behalf) | | | | |
| Voluntary coverage, obtained through individual or household premiums (which may benefit from tax-financed public subsidies, means-tested or not) | | | | |
| Other: | | | | |
| Please specify the coverage mechanism if "Other" is selected in the accompanying | | | | |
| box Vou can calcat multiple aptions | | | | |
| You can select multiple options | | | | |
| | | | | |
| | | | | |
| 90 | | | | |
| Are there any legal provisions pertaining to the benefit package in the specified scheme? | | | | |
| Please choose only one of the following: | | | | |
| Yes | | | | |
| ○ No | | | | |
| | | | | |
| 91 Please upload any relevant documents if you wish to do so. | | | | |
| Only answer this question if the following conditions are met: Answer was 'Yes' at question '90 [HFS2a]' (Are there any legal provisions pertaining to the benefit package in the specified scheme?) | | | | |
| Kindly attach the aforementioned documents along with the survey | | | | |
| | | | | |

| 92 Are decisions around the benefit package linked to a formalized HTA process? |
|---|
| Please choose only one of the following: |
| Yes. Please provide details in the comment box. No |
| Make a comment on your choice here: |
| |
| 93 Which actors/organizations internal to your country are involved in the discussions around the benefit package design? Please write your answer here: |
| |

| 94 Are benefit package decisions or processes conducted in collaboration with organizations external to your country? |
|--|
| Please choose all that apply: |
| Yes, with an international consortium or network Yes, with external donors as part of development assistance (including vertical programs for HIV/TB, vaccination, family planning, etc.) No Other: |

| Pharmaceuticals/Medicine Medical Procedures Medical Devices Diagnostic Tests Population Level Health Interventions(i.e. large | | | |
|---|-----------------------|---------|--|
| Medical Devices Diagnostic Tests Population Level Health | | | |
| Diagnostic Tests Population Level Health | | | |
| Population Level Health | | | |
| | | | |
| scale screening/vaccination programs) | | | |
| Others (Please Specify) | | | |
| ou may select multiple options for each cat A 'positive list' contains an enumeration of s A 'negative list' contains an enumeration of | services that are pro | ovided. | |

| 97 Which of the following elements are considered as coverage conditions for interventions in the benefit package? Please elaborate in the box upon selecting your choices. |
|---|
| Please choose all that apply and provide a comment: |
| Which population groups can access services (e.g. based on age, geography, socioeconomic status, etc.) |
| Which interventions are available (i.e. only cover generics or low-cost alternatives) |
| Where interventions can be delivered (e.g. physician gate-keeping, level of service delivery, etc.) |
| Cost-sharing arrangements (e.g. co-payments, deductibles, caps, cost recovery, etc.) |
| Waiting times to receive services |
| Other |
| You can select multiple options Please provide details with your selections |
| 98 Are there periodic revisions to the contents of the health benefit package? Please choose only one of the following: Yes No |

| 99 Please specify the time period for regular revisions. |
|---|
| Only answer this question if the following conditions are met: Answer was 'Yes' at question '98 [RHBP1]' (Are there periodic revisions to the contents of the health benefit package?) |
| Please choose only one of the following: |
| In a period under a year (e.g. every 6 months) |
| Between 1 and 3 years |
| Between 3 and 5 years |
| In a period that is over 5 years (e.g. every 10 years) |
| |
| |
| 100 What are the common forms of revisions of the health benefit package? Only answer this question if the following conditions are met: |
| 100 What are the common forms of revisions of the health benefit package? Only answer this question if the following conditions are met: Answer was 'Yes' at question '98 [RHBP1]' (Are there periodic revisions to the contents of the health benefit package?) |
| Only answer this question if the following conditions are met: Answer was 'Yes' at question '98 [RHBP1]' (Are there periodic revisions to the contents of |
| Only answer this question if the following conditions are met: Answer was 'Yes' at question '98 [RHBP1]' (Are there periodic revisions to the contents of the health benefit package?) |
| Only answer this question if the following conditions are met: Answer was 'Yes' at question '98 [RHBP1]' (Are there periodic revisions to the contents of the health benefit package?) Please choose all that apply: |
| Only answer this question if the following conditions are met: Answer was 'Yes' at question '98 [RHBP1]' (Are there periodic revisions to the contents of the health benefit package?) Please choose all that apply: Additions to the Benefit Package |
| Only answer this question if the following conditions are met: Answer was 'Yes' at question '98 [RHBP1]' (Are there periodic revisions to the contents of the health benefit package?) Please choose all that apply: Additions to the Benefit Package Withdrawals from the benefit package Changes in conditions of "covered use" (e.g. restricted target population, second line |
| Only answer this question if the following conditions are met: Answer was 'Yes' at question '98 [RHBP1]' (Are there periodic revisions to the contents of the health benefit package?) Please choose all that apply: Additions to the Benefit Package Withdrawals from the benefit package Changes in conditions of "covered use" (e.g. restricted target population, second line treatment) |

Contents of Health Benefit Package - General Interventions

For the following questions related to the health benefits package, please answer for the largest, national-level, or appropriate sub national level public coverage scheme in your country.

Your answers for what is covered or not covered should be applicable to the related health benefits package regardless of whether you have a positive list, defined by what you do cover, or a negative list, defined by what you exclude.

(i.e. mark not covered if an intervention is included on a negative list)

101 If available, please upload a document listing the <u>interventions covered</u> in the benefit package under the scheme you have answered this survey for.

Kindly attach the aforementioned documents along with the survey

You may upload additional documents detailing the benefit packages of other relevant schemes in your country.

| 4 | \cap | • |
|---|--------|---|
| | U | 4 |

For the following general categories, please respond to whether they are covered in the health benefit package for the identified scheme.

Please choose the appropriate response for each item:

| | Yes | Uncertain | No |
|--|------------|------------|------------|
| General Outpatient Consultation | \bigcirc | | \bigcirc |
| Specialist Outpatient Consultation | \bigcirc | | \circ |
| Ambulance Services | \bigcirc | \bigcirc | \bigcirc |
| Emergency unit care | | \bigcirc | \bigcirc |
| Acute inpatient care | | \bigcirc | \bigcirc |
| Critical Care (e.g. Intensive Care Unit) | \bigcirc | \bigcirc | \bigcirc |

| 4 | \sim | |
|-----|--------|---|
| 7 | 11 | - |
| - 1 | ι, | |

As indicated by you, the following interventions are covered in the health benefit package for the identified scheme. Hence, kindly indicate the financial arrangements for the selected interventions.

| | Free at point of care | Fixed Co- payment | Percentag Co- payment | Other | I am uncertain about the financial arrangemer |
|--|-----------------------|-------------------------|-----------------------------|-------|---|
| General Outpatient Consultation | | | | | |
| Specialist Outpatient Consultation | | | | | |
| Ambulance (emergency/non- emergency) | | | | | |
| Emergency unit care | | | | | |
| Acute inpatient care | | | | | |
| Critical Care (e.g. Intensive Care Unit) | | | | | |

- A copayment is an amount paid by a patient or individual for a particular health service. The
 copayment may either be set as a fixed number ('fixed copayment'), or as a percentage of the
 cost of the service ('percentage copayment')
- You can select multiple options.
- Please add any extra information on the financing options in the comment box provided. If you select the Other option, please provide more details in the comment box.

| Comment Box - | Comment box is below |
|--|----------------------|
| 104 Please add your comment in the box | helow |
| Please write your answer here: | Delow |
| | |
| | |
| | |

Contents of Health Benefit Package - Condition Specific Interventions

For the following questions that ask about tracer interventions for specific conditions, please answer for the largest, national-level, or appropriate sub national level public coverage scheme in your country.

Your answers for what is covered or not covered should be applicable to the related health benefits package regardless of whether you have a positive list, defined by what you do cover, or a negative list, defined by what you exclude.

(i.e. mark not covered if an intervention is included on a negative list)

| | Medication review and withdrawal of unnecessary or harmful medication | Multimodal exercise programmes including strength resistance training, aerobic training, balance training, flexibility training | Provision of assistive device | Home assessment and environmental adaptations for mobility ease and safety |
|--|---|---|-------------------------------------|--|
| Older adult health (Condition: limited mobility; Intervention: to improve mobility) | | | | |
| Select all the interventions that If possible, please list any releventions that box provided. | _ | · | • | the comment |
| 106 Please add your commen | | w | | |
| | | | | |

| | Antenatal care package | Antenatal Ultrasound | Normal childbirth (delivery in a health facility with skilled attendants) | Caesarean Delivery (for medical indications) |
|--|------------------------------|-------------------------|---|--|
| Maternal health | | | | |
| | | | | |
| 108 | | | | |
| Please add your comment i | | | | |
| 108 Please add your comment i Please write your answer | | | | |

| | Monitoring of early childhood development | Immunization (e.g. pneumococc vaccine, rotavirus and measles vaccines) | support for | Specialized care for developmental delays and disorders |
|------------------------------------|--|--|----------------------|---|
| Childhood | | | | |
| box provided. | | | i iliaications ili t | the comment |
| box provided. | <u>-</u> | | | me comment |
| 110 Please add your comment in the | e box below | | | me comment |
| 110 | | | | |

| | Neonatal resuscitaion (e.g. CPAP, oxygen therapy, suction) | Supplementary and parenteral nutrition (e.g. cup- feeding, naso-gastric feeding) | Exanguinotran | Neonatal surgery for complications of prematurity |
|---|---|--|----------------------|---|
| Newborn health | | | | |
| | any relevant cover | age conditions/me | dical indications i | n the comment |
| box provided. | any relevant covera | age conditions/me | dical indications i | n the comment |
| If possible, please list box provided. 112 | | | dical indications i | n the comment |
| box provided. | nent in the box belo | | dical indications in | n the comment |
| oox provided. 112 Please add your comm | nent in the box belo | | dical indications i | n the comment |
| 112 Please add your comm | nent in the box belo | | dical indications in | n the comment |

| | Identification stabilization and referral | Repair and counselling of minor birth defects, e.g. Club foot casting | Cleft lip and palate surgery | Congenital heart defects surgery |
|---|--|---|------------------------------------|---|
| Congenital malformations | | | | |
| | | | | |
| 114 | | | | |
| Please add your comment i | | | | |
| Please add your comment i | | | | |
| Please add your comment i | | | | |
| 114 Please add your comment in Please write your answer | | | | |

| | Supervised strengthenin exercises | Provision of orthotics (splints, braces, casts etc) for maintaining range of movement | Botulinum toxin for spasticity management | Provision of a motorized wheelchair (also called, electric wheelchair, electric- powered wheelchair, or powerchair) |
|---|---|---|--|---|
| Rehabilitation for motor functions and mobility | | | | |
| If possible, please list any rele | evant coverage co | naitions/medica | u indications in t | na commant |
| box provided. | | | | e comment |
| 116 Please add your comment in t | | | | The Comment |

| | Residual limb and stump care (including skin care, and education on positioning) | Provision of basic mobility devices (e.g. crutches, wheelchair) | Provision and training of lower limb prosthesis | Rehabilitation programs (for amputees with prosthesis) to return to sports and/or work |
|---|--|---|---|--|
| Rehabilitation afte | | | | |
| f possible, please list | any relevant coverage co | your benefit pac inditions/medica | _ | the comment |
| f possible, please list | | • | _ | the comment |
| f possible, please list | any relevant coverage co | • | _ | the comment |
| f possible, please list pox provided. 118 Please add your comm | any relevant coverage co | • | _ | the comment |
| | any relevant coverage co | • | _ | the comment |

| | Nutrition assessment | Dietician consultation | Multimodal weight loss interventions | Bariatric surgery |
|---|--|--------------------------------------|--------------------------------------|-----------------------------------|
| Nutrition (Life Course) | | | | |
| Select all the interventions that possible, please list any rele | - | - | • | he comment |
| 120 Please add your comment in the Please write your answer he | | | | |
| • | ie. | | | |
| | group, kindly indic | | | |
| | group, kindly indic | eme. Please che Breast feeding | | |
| 121 For the listed condition of the health benefit package for Nutrition (Infant and Child) | group, kindly indiction the identified scheme Provision of vitamin | eme. Please che Breast feeding | eck all that apply | Facility- based therapeutic |

| 122 Please add your comment in Please write your answer h | | | | |
|---|----------------------------------|-------------------------------------|--|------------------------------|
| | | | | |
| 123 For the listed condition the health benefit package for | | | | |
| | Morphine and other opioids | Home based palliative care | Psychologica social and spiritual care including bereavement support | Inpatient hospice care |
| Palliative care Select all the interventions the lift possible, please list any re | | - | _ | he comment |
| box provided. | - | | | |
| 124 Please add your comment in | the box below | | | |
| Please write your answer h | ere: | | | |
| | | | | |

| | Children's vision assessment | Prescription spectacles | of | Laser photocoagulat for diabetic eye disease |
|--|------------------------------|-------------------------|----|--|
| Decreased visual acuity | | | | |
| | | | | |
| 126 | | | | |
| 126 Please add your comment in the Please write your answer he | | | | |

| | Routine and preventive oral / dental care | Essential curative oral /dental care (including non- surgical extraction and drainage of abscesses) | Advanced curative oral / dental care (including re composite and dental amalgam including x-rays, complex fillings, root canal treatment). | Rehabilitation oral / dental care (including crowns and bridges, dentures, orthodontics dental implants). |
|---|---|---|--|---|
| Oral health | | | | |
| Select all the intervention of possible, please list an box provided. | | - | • | the comment |
| | | | | |
| 128 Please add your commer Please write your answ | | | | |

| | | Audiometry | Hearing aid provision | Rehabilitative therapy (eg auditory-verbal therapy) | Cochlear implants |
|---|------------------|--|-----------------------|--|----------------------|
| Hearing Defici | t | | | | |
| Select all the inter f possible, please pox provided. | | | • | • | the comment |
| | | | | | |
| Please add your o | | | | | |
| 130 Please add your o Please write you | | | | | |
| Please add your o | | | | | |
| Please add your o | | | | | |
| Please add your o | | | | | |
| Please add your o | | | | | |
| Please add your o | | | | | |
| Please add your o | r answer here | | cate which of th | ne interventions a | are covered in |
| Please add your o | r answer here | : oup, kindly indi | | eck all that apply | |
| Please add your of Please write your of Please write your of the lister | ed condition gro | : oup, kindly indi | neme. Please ch | | <i>1</i> . |
| Please add your o | ed condition gro | oup, kindly indi e identified sch Gliclazide or other | neme. Please ch | eck all that apply Insulin, regular and intermediate | Retinopathy |

| 132 Please add your comment in the box below |
|--|
| Please write your answer here: |
| |
| |
| |
| |
| |

| Two of the following | | | |
|-------------------------|-------------|--------------|--------------------|
| antihyperten | | | |
| a) | | | |
| Amlodipine, | | | |
| b) Enalapril | | | |
| or other | | | |
| angiotensin | | | |
| converting | | | |
| enzyme | | | |
| inhibitor | | | |
| (ACEI), c) | | | |
| hydrochlorot | | | |
| or | | | |
| Chlorthalido | | | |
| or d) | | | |
| Bisoprolol | | | |
| or | | | |
| alternative | | | |
| betablocker | | | |
| (atenolol or carvedilol | | | Coronary |
| or | Simvastatin | Percutaneou | Coronary |
| metoprolol | or other | coronary | u artery bypass |
| only) | statin | intervention | graft |
| | | | |

| Please write your answe | er here: | | | |
|--|--------------------------|--------------------|---------------------|------------------------|
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| 135 For the listed condit | | | | |
| me neam benem package | e for the fuertified Scr | ieilie. Fiease Cii | Salbutamol, | Beclometaso |
| | | Pulmonary function | Formoterol, | or other corticosteroi |
| | Spirometry | testing | Ipratropium | inhaler |
| COPD/Asthma | | | | |
| Select all the interventions | s that are included in | your benefit pac | :kage. | |
| | relevant coverage co | onditions/medica | al indications in t | the comment |
| | | | | |
| box provided. | | | | |
| | | | | |
| box provided. | | | | |
| | t in the box below | | | |
| box provided. | | | | |
| box provided. 136 Please add your comment | | | | |
| box provided. 136 Please add your comment | | | | |

| f possible, please list any relevant coverage conditions/medical indications in the comment pox provided. | | Nephrology consultation | erythropoies stimulating agents. One of the following: Epoetin alfa. Darbepoetin alfa | Dialysis (peritoneal or haemodialys | Renal transplant |
|---|--|----------------------------|--|--|---------------------|
| | End-stage renal disease | | | | |
| | Select all the interventions that f possible, please list any relev | | - | _ | he comment |
| | Select all the interventions that f possible, please list any relevence pox provided. | vant coverage co | - | _ | he comment |
| i | Select all the interventions that If possible, please list any releventions that box provided. | e box below | - | _ | he comment |

| | Cervical cancer screening with VIA | Cervical cancer screening with HPV test | Screening mammograp for breast cancer | Screening FIT, FOBT or endoscopy for colorectal cancer |
|--|---|---|--|--|
| Cancer Screening | | | | |
| | | | | |
| 140 | | | | |
| 140 Please add your comment i Please write your answer | | | | |

| | Modified radical mastectomy | for adjuvant or metastatic breast cancer, (HER2 testing + treatment) | | Breast reconstruction after mastectomy |
|---------------|-----------------------------------|--|---------------------|---|
| Breast Cancer | | | | |
| | ant coverage co | nditions/medica | Il indications in t | he comment |
| box provided. | ant coverage co | nditions/medica | Il indications in t | he comment |
| | - | nditions/medica | Il indications in t | he comment |
| box provided. | e box below | nditions/medica | Il indications in t | he comment |

| | Radical hysterectom | Radiotherapy (including brachytherap for curative cervical cancer | Advanced radiotherapy technique (IMRT, IGRT, image-guided brachytherap | PET/CT for staging of cervical cancer |
|-----------------|------------------------|--|--|--|
| Cervical Cancer | | | | |
| | vanit coverage co | multions/medica | l indications in t | the comment |
| box provided. | vanit coverage co | inditions/medica | I indications in t | the comment |
| | | Tultions/medica | i indications in t | the comment |
| box provided. | ne box below | Truttions/medica | i indications in t | the comment |

| | Surgery for lung cancer (wedge resection, lobectomy) | Adjuvant radiotherapy for lung cancer | Targeted therapy (EGFR mutation inhibitor) for metastatic lung cancer, (EGFR testing + treatment) | Immunothera for metastatic lung cancer |
|---|---|---------------------------------------|---|--|
| Lung Cancer | | | | |
| box provided. | | | | |
| | nt in the boy below | | | |
| 146 Please add your comme Please write your answ | | | | |

| | Immunohisto staining for morphologic diagnosis of childhood cancers | Outpatient (ambulatory) chemotherap (for less intensive treatment phases), (First line agents for ALL) | Extremity / ocular prostheses, TKI for +Ph ALL, (testing + treatment) | Stem cell transplantatio |
|--|---|--|---|-----------------------------|
| Acute lymphoid leukemia | | | | |
| Select all the interventions t If possible, please list any re box provided. | • | • | • | the comment |
| Select all the interventions t If possible, please list any re box provided. | • | • | • | the comment |
| Select all the interventions t | elevant coverage co | • | • | the comment |
| Select all the interventions to the select all the interventions to the select any restriction of the select and the select and the select all the select and the select all the interventions to the select all the sel | elevant coverage co | • | • | the comment |

| | Assessment of seizure disorder and provision of oral anti- seizure medications | Management of status epilepticus | Therapeutic drug level monitoring and second-line antiseizure medicines | Epilepsy surgery |
|--------------------------------|--|--|---|---------------------|
| Epilepsy | | | | |
| | | | | |
| 150 Please add your comment | in the box below | | | |
| | | | | |

| | Assessment of psychosis and psychoeduca for person and carers | and, if indicated, anticholinerg | Recovery/rehoriented strategies for psychosis | Multi- disciplinary specialist service for psychosis |
|--|---|----------------------------------|---|--|
| Psychosis (in adults) | | | | |
| Select all the interventions tha | - | • | _ | he comment |
| Select all the interventions that f possible, please list any relebox provided. | vant coverage co | • | _ | he comment |
| Select all the interventions that If possible, please list any relebox provided. 152 Please add your comment in the Please write your answer he | vant coverage co | • | _ | he comment |

| 153 For the listed condition grather the health benefit package for the | | | | |
|--|---|---|---|--|
| | Screening, brief interventions and psychosocia treatment in PHC and settings not specialized for treatment of substance use disorders | | | Specialized long-term inpatient or residential treatment (rehabilitation for substance use disorders |
| Substance use disorders | | | | |
| Select all the interventions that If possible, please list any relev box provided. | | • | • | the comment |
| 154 Please add your comment in the Please write your answer here | | | | |

| | Assessment of depression and psychoeduca for person and carers | Brief psychologica interventions for depression and provision of first line antidepressa medication (SSRIs or TCAs) | Full course of psychotheral (e.g., CBT, interpersona therapy) by a psychologist or psychiatrist | Multi- disciplinary |
|---|--|---|---|------------------------|
| Depression (in adults) | | | | |
| Select all the interventions that If possible, please list any relev | - | · | _ | he comment |
| f possible, please list any relev | - | · | _ | he comment |
| f possible, please list any releved to provided. | ant coverage co | · | _ | he comment |
| | e box below | · | _ | he comment |

| | Laceration repair | Casting fracture | Open reduction and internal fixation | Escharotom |
|---|--------------------|---------------------|--------------------------------------|------------|
| Injury/Burns | | | | |
| 158 | | | | |
| | t in the box below | | | |
| Please add your commen | | | | |
| Please add your commen Please write your answe | er here: | | | |

| f possible, please list any relevant coverage conditions/medical indications in the comment box provided. 160 Please add your comment in the box below | | HIV drug sensitivity testing | Combination anti-retroviral therapy for first line treatment of HIV. One of the following combinations individually for concomitant use or in fixed- dose combination: Efavirenz + Emtricitabine + Tenofovir disoproxil fumarate. Efavirenz + Lamivudine + Tenofovir disoproxil fumarate | Post-exposure prophylaxis for HIV (PEP) | Pre-exposure prophylaxis for HIV (PREP) |
|--|----------------|------------------------------------|--|---|---|
| Select all the interventions that are included in your benefit package. If possible, please list any relevant coverage conditions/medical indications in the comment box provided. 160 Please add your comment in the box below Please write your answer here: | HIV | | | | |
| | f possible, pl | ease list any relevan | _ | | s in the comment |
| | 60 | | | | |

| | | TB liagnostics (including sputum smear and chest x- ray) | Isoniazid + pyrazinamide | GeneXpert/R assay | Lobectomy |
|---|------------------|--|--------------------------|----------------------|-------------|
| | | | | | |
| f possible, please | | | - | = | the comment |
| Select all the inter f possible, please pox provided. | | | - | = | the comment |
| Select all the inter f possible, please pox provided. | list any relevan | t coverage co | - | = | the comment |
| Select all the inter f possible, please fox provided. | list any relevan | t coverage co | - | = | the comment |
| Select all the inter f possible, please pox provided. | list any relevan | t coverage co | - | = | the comment |

| | | Provision of Insecticide Treated Nets (ITNs) in health | Chemopreve in high risk | ACT for treatment of confirmed uncomplicate | Treatment of severe malaria, with injectable artesunate (intramuscula or intravenous) for at least 24 hours and followed by a complete 3-day course of an artemisinin- based combined therapy |
|--|--|---|-------------------------|---|---|
| | | facilities | groups | malaria | (ACT) |
| Malaria | | | | | |
| Select all the in | nterventions that ease list any relev | | - | _ | the comment |
| Select all the in if possible, ple box provided. | | e box below | - | _ | the comment |

| | Hepatitis B three-dose vaccination | Chronic hepatitis C treatment with direct acting antivirals | Liver biopsy and pathology | Liver translplant |
|--------------------------|--|---|----------------------------------|----------------------|
| Viral hepatitis | | | | |
| 166 | | | | |
| Please add your comment | in the box below | | | |
| Please write your answei | here: | | | |
| | | | | |

| - 1141 | | medicines | Medicine | treatments |
|--|----------------------|-----------|----------|------------|
| Traditional and Complimentary Medicine | | | | |
| If possible, please list any rele box provided. You may also use the comme Interventions that are covered | nt box to list any o | | | |
| 168 Please add your comment in t Please write your answer he | | | | |

| | • | Family planning / contracep using short acting hormonal methods, including injectables | acting methods of contracep (IUDs and | Emergency contracept (any | |
|---|-----------|--|--|---------------------------------|--|
| Sexual and reproductive health - Contraception | | | | | |
| If possible, please list any relevatory box provided. | | | | | |
| | | | | | |
| 170 Please add your comment in the | box below | | | | |
| | | | | | |

| | Screening and treatment for STIs | Management of menstrual disorders and menopause | Treatment for sexual dysfunction | Treatment for infertility |
|--|---|---|--|---------------------------------|
| Sexual and reproductive health - Sexual Health | | | | |
| oox provided. | ant dovoluge of | | Tindications in t | me comment |
| | ant ooverage of | | Timulcations in t | me comment |
| pox provided. | | | Timulcations in t | me comment |
| 172 Please add your comment in th | e box below | | Timulcations in t | me comment |
| 172 Please add your comment in th | e box below | | Timulcations in t | The Comment |
| pox provided. | e box below | | Timulcations in t | The Comment |

| | Induced abortion (medical or surgical) up to 12 weeks | Induced abortion (medical or surgical) after 12 weeks | Care for miscarriage or incomplete abortion with medical and/or surgical uterine evacuation | Care for complication of unsafe abortion with medical and/or surgical uterine evacuation |
|---|--|--|---|--|
| Sexual and reproductive health - Abortion Care | | | | |
| Select all the interventions that for possible, please list any releved pox provided. | | • | _ | the comment |
| f possible, please list any releved box provided. | vant coverage co | • | _ | the comment |
| f possible, please list any relev | e box below | • | _ | the comment |

| | of FGM- related health | Management of Type III FGM, including deinfibulation | and communicati for FGM | Care for mental health and sexual health complication of FGM by trained providers |
|--|------------------------------|--|-------------------------------|---|
| Sexual and reproductive health - Female Genital Mutilation | | | | |
| Select all the interventions that | - | • | • | the comment |
| Select all the interventions that for possible, please list any relevoox provided. | - | • | • | the comment |
| f possible, please list any relevence pox provided. 176 Please add your comment in the | vant coverage co | • | • | the comment |
| f possible, please list any rele | vant coverage co | • | • | the comment |

| | Identification, care and support for IPV | Care and support for sexual violence, including acute post-rape care |
|--|--|--|
| Sexual and reproductive health - Gender based violence | | |
| | | |
| 178 | | |
| 178 Please add your comment in the | e box below | |
| | | |

Contents of Health Benefit Package - Sexual and Reproductive Health and Rights

The following two questions ask about specific health benefit package issues related to the inclusion of interventions for Sexual and Reproductive Health and Rights (SRHR).

| 179 Do you use any pre-existing lists or frames of services to inform the coverage of sexual and reproductive health interventions in your benefit package? (e.g. the Minimum Initial Service Package (MISP) for reproductive health in fragile & conflict-affected settings). |
|--|
| Please choose only one of the following: |
| Yes |
| ○ No |
| Make a comment on your choice here: |
| If yes, please list the specific lists or frames. |
| 180 Are any of the following reasons for exclusion of specific sexual and reproductive health services from the health benefits package? Please choose all that apply: |
| Politically contested |
| Insufficient evidence to meet the requirements of the priority setting criteria |
| Insufficient participation or exclusion of relevant stakeholders |
| Excluded because it was funded by donors |
| Other: |

Contents of Health Benefit Package - Medications

For the following question related to medications, please answer for the largest, national-level, or appropriate sub national level public coverage scheme in your country.

Your answers for what is covered or not covered should be applicable to the related health benefits package regardless of whether you have a positive list, defined by what you do cover, or a negative list, defined by what you exclude.

(i.e. mark not covered if an intervention is included on a negative list)

181 Please respond as applicable assessing whether the listed medications are covered, partially covered or not covered by the health benefit package of the scheme in your country.

Please choose the appropriate response for each item:

| | Fully Covered | Partially Covered | | Uncertai |
|---|------------------|----------------------|------------|------------|
| Acetylsalicylic acid (aspirin) | \bigcirc | \bigcirc | \bigcirc | \bigcirc |
| Furosemide | \bigcirc | \bigcirc | \bigcirc | \bigcirc |
| Paracetamol | \bigcirc | \bigcirc | \bigcirc | \bigcirc |
| Phenytoin or Carbamazepine | \bigcirc | \bigcirc | \bigcirc | \bigcirc |
| Gentamicin | \bigcirc | \bigcirc | \bigcirc | \bigcirc |
| Amoxicillin | \bigcirc | \bigcirc | \bigcirc | \bigcirc |
| Ceftriaxone | \bigcirc | \bigcirc | \bigcirc | \bigcirc |
| Procaine benzylpenicillin injection or Benzathine benzylpenicillin injection | \bigcirc | \bigcirc | \bigcirc | \bigcirc |
| Oral rehydration salts | \bigcirc | \bigcirc | \bigcirc | \bigcirc |
| Zinc sulphate | \bigcirc | \bigcirc | \bigcirc | \bigcirc |
| Oxytocin injection | \bigcirc | \bigcirc | \bigcirc | \bigcirc |
| Magnesium sulphate Injection | \bigcirc | \bigcirc | \bigcirc | \bigcirc |
| Folic acid | \bigcirc | \bigcirc | \bigcirc | \bigcirc |
| lbuprofen | \bigcirc | \bigcirc | \bigcirc | \bigcirc |
| Chlorhexidine Solution or gel: (digluconate) delivering chlorhexidine | \bigcirc | \bigcirc | \bigcirc | \bigcirc |
| Ready-to-use therapeutic food (RUTF), paste or spread or biscuit | \bigcirc | \bigcirc | \bigcirc | \bigcirc |
| One of the following: Epinephrine injection (as hydrochloride or hydrogen tartrate) in Ampoule Dexamethasone injection/Ampoule (as disodium phosphate salt) | | | | |
| Mifepristone | | \bigcirc | | |

| | Fully Covered | Partially Covered | | Uncertain |
|---|------------------|----------------------|------------|------------|
| Misoprostol | | \bigcirc | \bigcirc | \bigcirc |
| Combinations of mifepristone and misoprostol, including individual or combinack presentations | 0 | \bigcirc | \bigcirc | |
| Fluconazole and Nystatin | \bigcirc | \bigcirc | \bigcirc | |
| Levothyroxine | | \bigcirc | \bigcirc | |
| Cisplatin | | \bigcirc | \bigcirc | |
| Asparaginase | \bigcirc | \bigcirc | \bigcirc | |
| Erlotinib | | \bigcirc | \bigcirc | |
| Nivolumab | | \bigcirc | \bigcirc | \bigcirc |
| Cyclophosphamide | | \bigcirc | \bigcirc | \bigcirc |
| Filgastrim | \bigcirc | \bigcirc | \bigcirc | |
| Mercaptopurine | \bigcirc | \bigcirc | \bigcirc | |

- Fully Covered The medication is covered in the health benefit package and provided free at point of care.
- Partially Covered The medication is covered in the health benefit package with a cost sharing mechanism such as a co-payment* or co-insurance*
- Not Covered The medication is not covered in the health benefit package

Final Comments and Authorization

| Please write your answe | er here: | |
|---------------------------------|--|--|
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| 83 | | |
| Please tick: | | |
| Please choose all that a | apply: | |
| | ormation to be true to the best of our knowledge | |
| | to use any information submitted in this survey | |
| | submitting these responses as the nominated focal point ave authority delegated from the nominated focal point | |

| DataForm Extranet - Health Technology Assessment/Health Renefit Page 1988 | aakaaa Suryay 202 |
|---|-------------------|

| WHO HQ would like to conduct deep dives with some country respondents to further enrich our understanding of the HTA process. Would you be willing to participate and assist us in this process? Please respond: * Please choose only one of the following: Yes No Ink you for your valuable time and participation in this survey. Ink you for completing this survey. The space below to add any more information if needed:- | | <i>c.</i> |
|---|--------------|---|
| WHO HQ would like to conduct deep dives with some country respondents to further enrich our understanding of the HTA process. Would you be willing to participate and assist us in this process? Please respond: * Please choose only one of the following: Yes No Ink you for your valuable time and participation in this survey. which your survey. Ink you for completing this survey. | | |
| WHO HQ would like to conduct deep dives with some country respondents to further enrich our understanding of the HTA process. Would you be willing to participate and assist us in this process? Please respond: * Please choose only one of the following: Yes No Ink you for your valuable time and participation in this survey. which your survey. Ink you for completing this survey. | 1: | 34 |
| Please choose only one of the following: Yes No Ink you for your valuable time and participation in this survey. Omit your survey. Ink you for completing this survey. | W re p | THO HQ would like to conduct deep dives with some country espondents to further enrich our understanding of the HTA rocess. Would you be willing to participate and assist us in this |
| Please choose only one of the following: Yes No Ink you for your valuable time and participation in this survey. Omit your survey. Ink you for completing this survey. | - | rocess? Please respond: |
| Yes No Ink you for your valuable time and participation in this survey. Omit your survey. Ink you for completing this survey. | * | |
| No nnk you for your valuable time and participation in this survey. Omit your survey. Ink you for completing this survey. | Pl | ease choose only one of the following: |
| omit you for completing this survey. | | Yes |
| omit you for completing this survey. | |) No |
| omit your survey. Ink you for completing this survey. | | |
| nk you for completing this survey. | เท | k you for your valuable time and participation in this survey. |
| nk you for completing this survey. | om | it your survey. |
| | | |
| ne space below to add any more information if needed : - | | |
| | the | space below to add any more information if needed : - |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |